312 related articles for article (PubMed ID: 25108408)
1. Correlation Between E-cadherin Immunoexpression and Efficacy of First Line Platinum-Based Chemotherapy in Advanced High Grade Serous Ovarian Cancer.
Miše BP; Telesmanić VD; Tomić S; Šundov D; Čapkun V; Vrdoljak E
Pathol Oncol Res; 2015 Apr; 21(2):347-56. PubMed ID: 25108408
[TBL] [Abstract][Full Text] [Related]
2. Prognostic role of E-cadherin in patients with advanced serous ovarian cancer.
Bačić B; Haller H; Mrklić I; Košta V; Čarić A; Tomić S
Arch Gynecol Obstet; 2013 Jun; 287(6):1219-24. PubMed ID: 23269354
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of MAPK, Topo IIα and E-cadherin immunoexpression in ovarian serous carcinomas.
Sundov D; Petric Mise B; Mrklic I; Bacic B; Vrdoljak E; Tomic S
Neoplasma; 2017; 64(2):289-298. PubMed ID: 28052682
[TBL] [Abstract][Full Text] [Related]
4. Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma.
Liu Y; Yasukawa M; Chen K; Hu L; Broaddus RR; Ding L; Mardis ER; Spellman P; Levine DA; Mills GB; Shmulevich I; Sood AK; Zhang W
JAMA Oncol; 2015 Jul; 1(4):486-94. PubMed ID: 26181259
[TBL] [Abstract][Full Text] [Related]
5. Prognostic and predictive values of E-cadherin for patients of ovarian clear cell adenocarcinoma.
Ho CM; Cheng WF; Lin MC; Chen TC; Huang SH; Liu FS; Chien CC; Yu MH; Wang TY; Hsieh CY
Int J Gynecol Cancer; 2010 Dec; 20(9):1490-7. PubMed ID: 21119364
[TBL] [Abstract][Full Text] [Related]
6. The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions.
Davidson B; Holth A; Hellesylt E; Tan TZ; Huang RY; Tropé C; Nesland JM; Thiery JP
Hum Pathol; 2015 Jan; 46(1):1-8. PubMed ID: 25455994
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of E-cadherin immunoexpression in patients with primary ovarian carcinomas.
Faleiro-Rodrigues C; Macedo-Pinto I; Pereira D; Lopes CS
Ann Oncol; 2004 Oct; 15(10):1535-42. PubMed ID: 15367415
[TBL] [Abstract][Full Text] [Related]
8. Tau protein as a potential predictive marker in epithelial ovarian cancer patients treated with paclitaxel/platinum first-line chemotherapy.
Smoter M; Bodnar L; Grala B; Stec R; Zieniuk K; Kozlowski W; Szczylik C
J Exp Clin Cancer Res; 2013 Apr; 32(1):25. PubMed ID: 23631819
[TBL] [Abstract][Full Text] [Related]
9. Prognostic and predictive values of Nrf2, Keap1, p16 and E-cadherin expression in ovarian epithelial carcinoma.
Liew PL; Hsu CS; Liu WM; Lee YC; Lee YC; Chen CL
Int J Clin Exp Pathol; 2015; 8(5):5642-9. PubMed ID: 26191276
[TBL] [Abstract][Full Text] [Related]
10. Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase.
Grabowski JP; Harter P; Heitz F; Pujade-Lauraine E; Reuss A; Kristensen G; Ray-Coquard I; Heitz J; Traut A; Pfisterer J; du Bois A
Gynecol Oncol; 2016 Mar; 140(3):457-62. PubMed ID: 26807488
[TBL] [Abstract][Full Text] [Related]
11. The prognostic and predictive value of syntactic structure analysis in serous carcinoma of the ovary.
Palmer JE; Sant Cassia LJ; Irwin CJ; Morris AG; Janssen EA; Baak JP; Rollason TP
Int J Gynecol Pathol; 2008 Apr; 27(2):191-8. PubMed ID: 18317224
[TBL] [Abstract][Full Text] [Related]
12. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
13. The effect of adjuvant chemotherapy on survival in patients with FIGO stage I high-grade serous ovarian cancer.
van Baal JOAM; Van de Vijver KK; Algera MD; van der Aa MA; Sonke GS; van Driel WJ; Kenter GG; Amant FC; Lok CAR
Gynecol Oncol; 2019 Jun; 153(3):562-567. PubMed ID: 30948193
[TBL] [Abstract][Full Text] [Related]
14. Clinical relevance of CD44 surface expression in advanced stage serous epithelial ovarian cancer: a prospective study.
Elzarkaa AA; Sabaa BE; Abdelkhalik D; Mansour H; Melis M; Shaalan W; Farouk M; Malik E; Soliman AA
J Cancer Res Clin Oncol; 2016 May; 142(5):949-58. PubMed ID: 26762850
[TBL] [Abstract][Full Text] [Related]
15. SLFN11 captures cancer-immunity interactions associated with platinum sensitivity in high-grade serous ovarian cancer.
Winkler C; King M; Berthe J; Ferraioli D; Garuti A; Grillo F; Rodriguez-Canales J; Ferrando L; Chopin N; Ray-Coquard I; Delpuech O; Rinchai D; Bedognetti D; Ballestrero A; Leo E; Zoppoli G
JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34549724
[TBL] [Abstract][Full Text] [Related]
16. Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.
Furlong F; Fitzpatrick P; O'Toole S; Phelan S; McGrogan B; Maguire A; O'Grady A; Gallagher M; Prencipe M; McGoldrick A; McGettigan P; Brennan D; Sheils O; Martin C; W Kay E; O'Leary J; McCann A
J Pathol; 2012 Apr; 226(5):746-55. PubMed ID: 22069160
[TBL] [Abstract][Full Text] [Related]
17. Predicting Response to Standard First-line Treatment in High-grade Serous Ovarian Carcinoma by Angiogenesis-related Genes.
Mendiola M; Redondo A; Heredia-Soto V; Herranz J; Berjón A; Hernández A; Miguel-Martín M; Crespo R; Barriuso J; Cruz P; Yébenes L; Peláez-García A; Castelo B; DE Molina AR; Feliu J; Hardisson D
Anticancer Res; 2018 Sep; 38(9):5393-5400. PubMed ID: 30194194
[TBL] [Abstract][Full Text] [Related]
18. Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data.
Cohen PA; Powell A; Böhm S; Gilks CB; Stewart CJR; Meniawy TM; Bulsara M; Avril S; Brockbank EC; Bosse T; de Azevedo Focchi GR; Ganesan R; Glasspool RM; Howitt BE; Kim HS; Lee JY; Le ND; Lockley M; Manchanda R; Mandalia T; McCluggage WG; McNeish I; Midha D; Srinivasan R; Tan YY; van der Griend R; Yunokawa M; Zannoni GF; ; Singh N
Gynecol Oncol; 2019 Aug; 154(2):441-448. PubMed ID: 31118141
[TBL] [Abstract][Full Text] [Related]
19. Association of E-cadherin and beta-catenin immunoexpression with clinicopathologic features in primary ovarian carcinomas.
Faleiro-Rodrigues C; Macedo-Pinto I; Pereira D; Ferreira VM; Lopes CS
Hum Pathol; 2004 Jun; 35(6):663-9. PubMed ID: 15188131
[TBL] [Abstract][Full Text] [Related]
20. Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base.
Canaz E; Grabowski JP; Richter R; Braicu EI; Chekerov R; Sehouli J
Gynecol Oncol; 2019 Sep; 154(3):539-546. PubMed ID: 31230821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
